ABSTRACT
SPf66, a chimeric first generation synthetic malarial vaccine, has been shown to be safe. immunogenic and able to induce a protective immune response against clinical malaria. This vaccine is a construct based on the combination of different peptides (35 . 1 ,55 . 1 , 8 3 . 1 ) derived from three merozoite proteins. These peptides are linked by the PNANP sequence derived from the sporozoitic stage' s immunodominant antigen (the Circumsporozoite Protein). The blood epitopes wcre selected on their ability to induce protective immunity in Aotus monkeys , experimentally challenged with infectious fonus of P. Jalciparum parasites .
